| P2093 | author name string | Sandrine Lecour | |
| | Richard W James | |
| P2860 | cites work | Omega-3 polyunsaturated fatty acids and cardiovascular diseases | Q27863409 |
| | Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress | Q28142513 |
| | Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure | Q28195394 |
| | Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy | Q28343848 |
| | The complex of ciliary neurotrophic factor-ciliary neurotrophic factor receptor alpha up-regulates connexin43 and intercellular coupling in astrocytes via the Janus tyrosine kinase/signal transducer and activator of transcription pathway | Q28565647 |
| | Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning | Q28771386 |
| | Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis | Q30697267 |
| | Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction | Q33331962 |
| | Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction | Q33348902 |
| | Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure | Q33611681 |
| | The Jak-STAT pathway | Q33899139 |
| | Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNFalpha gene | Q44088296 |
| | Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. | Q44768384 |
| | Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study | Q44799903 |
| | Mechanism of cardiac depression after trauma-hemorrhage: increased cardiomyocyte IL-6 and effect of sex steroids on IL-6 regulation and cardiac function | Q45099421 |
| | Free radicals trigger TNF alpha-induced cardioprotection | Q45203259 |
| | Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of sphingosine-1-phosphate | Q46158490 |
| | TNFalpha is required to confer protection in an in vivo model of classical ischaemic preconditioning | Q46224947 |
| | Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study | Q46489522 |
| | Physical exercise improves plasmatic levels of IL-10, left ventricular end-diastolic pressure, and muscle lipid peroxidation in chronic heart failure rats | Q46651733 |
| | Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). | Q46847925 |
| | Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization | Q46909913 |
| | Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naïve myocardium but is essential for the development of late preconditioning | Q47226424 |
| | Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy | Q47860383 |
| | Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial | Q47968070 |
| | Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. | Q50524441 |
| | Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. | Q51093781 |
| | Multiple protective pathways against reperfusion injury: a SAFE path without Aktion? | Q51752588 |
| | A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. | Q51767309 |
| | Tumor necrosis factor-alpha and its receptors 1 and 2: Yin and Yang in myocardial infarction? | Q51789753 |
| | Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. | Q53547618 |
| | Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. | Q54444876 |
| | Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling. | Q54467496 |
| | Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling. | Q54705304 |
| | Continuous Glycoprotein-130–Mediated Signal Transducer and Activator of Transcription-3 Activation Promotes Inflammation, Left Ventricular Rupture, and Adverse Outcome in Subacute Myocardial Infarction | Q57339890 |
| | Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure | Q57951046 |
| | Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure | Q59192155 |
| | Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart | Q33907789 |
| | An essential role of the JAK-STAT pathway in ischemic preconditioning | Q33929635 |
| | The cytoprotective effects of tumor necrosis factor are conveyed through tumor necrosis factor receptor-associated factor 2 in the heart | Q34022068 |
| | Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion | Q34300508 |
| | Innate immunity and cardiac preconditioning: a putative intrinsic cardioprotective program | Q34772373 |
| | Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? | Q34974091 |
| | Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs | Q35604862 |
| | Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 expression: role of the 55 kDa TNF receptor (TNFR1). | Q35606632 |
| | TNFα protects cardiac mitochondria independently of its cell surface receptors | Q36148170 |
| | Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects | Q36497007 |
| | Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age | Q36689956 |
| | Connexin 43 in ischemic pre- and postconditioning. | Q36827888 |
| | Can the protective actions of JAK-STAT in the heart be exploited therapeutically? Parsing the regulation of interleukin-6-type cytokine signaling | Q36912096 |
| | IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. | Q36952776 |
| | Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction | Q36977754 |
| | Cytokines and acute heart failure | Q37044902 |
| | Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial | Q37213020 |
| | Regulation of Mn-superoxide dismutase activity and neuroprotection by STAT3 in mice after cerebral ischemia | Q37265505 |
| | The myocardial JAK/STAT pathway: from protection to failure | Q37266843 |
| | Immunological mechanisms of pentoxifylline in chronic heart failure | Q37377105 |
| | Function of mitochondrial Stat3 in cellular respiration | Q37378567 |
| | Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor | Q37412421 |
| | JAK redux: a second look at the regulation and role of JAKs in the heart | Q37430884 |
| | TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure | Q37771751 |
| | Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor | Q38622547 |
| | The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta | Q40308442 |
| | Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options | Q40785303 |
| | Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure | Q40870003 |
| | Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy--lessons from animal experiments | Q41016937 |
| | Basic mechanisms in heart failure: the cytokine hypothesis | Q41188647 |
| | New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats | Q42463523 |
| | Ethanolamine is a novel STAT-3 dependent cardioprotective agent | Q42861824 |
| | Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation | Q43065625 |
| | High-density lipoprotein cholesterol levels and prognosis in advanced heart failure | Q43283941 |
| | Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis | Q43287633 |
| | Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway | Q43295255 |
| | Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). | Q43586296 |
| | Role of STAT3 in ischemic preconditioning | Q43799529 |
| | Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine | Q43966261 |
| | Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection | Q44022447 |
| P433 | issue | 6 | |
| P921 | main subject | inflammation | Q101991 |
| | heart failure | Q181754 |
| P304 | page(s) | 680-685 | |
| P577 | publication date | 2011-02-07 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | When are pro-inflammatory cytokines SAFE in heart failure? | |
| P478 | volume | 32 | |